ArticleScientific reports2021
Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Smoker's Lungs: Quo Vadis? Exploring the Shared and Individual Smoking-Related Molecular Pathways of Emphysema, Carcinoma, and Fibrosis - An Illustrative Review.Thoracic cancer · 2026Review
- Chronic obstructive pulmonary disease and risk of incident cardiovascular disease, chronic kidney disease, and death: a systematic review and meta-analysis.EClinicalMedicine · 2026Article
- Understanding sex and gender disparities in COVID-19 mortality: a narrative review beyond biology.Biology of sex differences · 2025Review
- Recent advancements in traditional Chinese medicine for COVID-19 with comorbidities across various systems: a scoping review.Infectious diseases of poverty · 2024Article
- AutoML-Driven Insights into Patient Outcomes and Emergency Care During Romania's First Wave of COVID-19.Bioengineering (Basel, Switzerland) · 2024Article
- COVID-19 vaccine updates for people under different conditions.Science China. Life sciences · 2024Review
- Risk factors for SARS-CoV-2 infection: a test-negative case-control study with additional population controls in Norway.BMJ open · 2024Article
- A Complex Interplay: Navigating the Crossroads of Tobacco Use, Cardiovascular Disease, and the COVID-19 Pandemic: A WHF Policy Brief.Global heart · 2024Review
- COVID-19 in Patients with Chronic Lung Disease.Clinics in chest medicine · 2023Review
- The immunogenetics of COVID-19.Immunogenetics · 2023Review
- An observational study on factors associated with ICU mortality in Covid-19 patients and critical review of the literature.Scientific reports · 2023Review
- Investigating the role of obstructive pulmonary diseases and eosinophil count at admission on all-cause mortality in SARS-CoV-2 patients : A single center registry-based retrospective cohort study.Wiener klinische Wochenschrift · 2023Article
- The association between risk perceptions, anxiety, and self-reported changes in tobacco and nicotine product use due to COVID-19 in May-June 2020 in Israel.BMC public health · 2023Article
- Review
- COVID-19 effect on patients with noncommunicable diseases: A narrative review.Health science reports · 2023Article
- Creating a provincial post COVID-19 interdisciplinary clinical care network as a learning health system during the pandemic: Integrating clinical care and research.Learning health systems · 2023Article
- Management Strategies of COPD during the COVID-19 Pandemic.Tanaffos · 2023Article
- Article
- Significant burden of post-COVID exertional dyspnoea in a South-Italy region: knowledge of risk factors might prevent further critical overload on the healthcare system.Frontiers in public health · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognosis of the coronavirus disease 2019 (COVID-19) patients is variable and depends on several factors. Current data about the impact of chronic obstructive pulmonary disease (COPD) and smoking on the clinical course of COVID-19 are still controversial. This study evaluated the prevalence and the prognosis of COPD patients and smokers in a cohort of 521 patients admitted to four intermediate Respiratory Intensive Care Units (Puglia, Italy) with respiratory failure due to COVID-19 pneumonia. The prevalence of COPD and current smokers was 14% and 13%, respectively. COPD patients had a higher 30-day all-cause mortality than non-COPD patients. Former smokers compared to never smokers and current smokers had higher 30-day all-cause mortality. COPD patients and former smokers had more comorbidities. This study described the prevalence and the outcomes of COPD patients and smokers in a homogenous cohort of COVID-19 patients. The study showed that the prevalence of COPD and current smokers was not high, suggesting that they were not at increased risk of getting the infection. However, when SARS-CoV-2 infection occurred, COPD patients and former smokers were those with the highest all-cause mortality, which seemed to be mainly related to the presence of comorbidities and not to COPD and smoking itself.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.